The company is so far trading down by 12.63% percent from yesterday’s close. The stock last traded at $0.83 which is quite a bit lower than $1.02, the 50 day moving average and which is significantly below the 200 day moving average of $1.34. The 50 day moving average was down $-0.19 or -18.49% and the 200 day average went down by -38.20%.
Investors are a little more bullish on Oasmia Pharmaceutical AB – Amer recently if you look at the change in short interest. The stock realized a fall in short interest of -28.45% as of the latest report on September 29, 2017. Short shares decreased 2,679 over that timeframe. With short interest at 6,736 and short average daily volume at 3,497, days to cover is 2.0 and the short interest percentage is 0.00% as of September 29.
Oasmia Pharmaceutical AB (publ) researches, develops, and manufactures drugs for human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company’s approved products include Paccal Vet-CA1 for the treatment of mammary carcinoma and squamous cell carcinoma in dogs; and Paclical for the treatment of ovarian cancer. It is also developing Paclical for the treatment of metastatic breast cancer; Doxophos, a formulation of the cytostatic doxorubicin, for the treatment of breast cancer; Docecal, a patented formulation of cytostatic docetaxel, for the treatment of breast cancer; and OAS-19 to treat various cancers. Its product candidates for animal health comprise Paccal Vet-CA1, a formulation of paclitaxel, for the treatment of mastocytoma in dogs; and Doxophos Vet for the treatment of lymphoma in dogs. Oasmia Pharmaceutical AB was founded in 1990 and is based in Uppsala, Sweden..
A few notable investment firms have updated their holdings. Sabby Management, LLC downsized its position by shedding 16,054 shares a decrease of 45.8% as of 06/30/2017. Sabby Management, LLC controls 19,000 shares worth $20,000. The value of the position overall is down by 69.7%. As of the end of the quarter Sio Capital Management, LLC had acquired 5,700 shares growing its holdings by 2.9%. The value in dollars went from $377,000 to $214,000 a change of $163,000 for the reporting period.
Ubs Group Ag augmented its investment by buying 7,217 shares an increase of 6,560.9%. Ubs Group Ag claims 7,327 shares with a value of $8,000. The total value of its holdings increased inf%.